p. 4145−4146
2476-762X
Vol.16/No.10
p. 4147−4156
2476-762X
Vol.16/No.10
p. 4157−4160
2476-762X
Vol.16/No.10
p. 4161−4168
2476-762X
Vol.16/No.10
p. 4169−4172
2476-762X
Vol.16/No.10
p. 4173−4176
2476-762X
Vol.16/No.10
p. 4177−4183
2476-762X
Vol.16/No.10
p. 4185−4192
2476-762X
Vol.16/No.10
p. 4193−4198
2476-762X
Vol.16/No.10
p. 4199−4202
2476-762X
Vol.16/No.10
p. 4203−4209
2476-762X
Vol.16/No.10
p. 4211−4214
2476-762X
Vol.16/No.10
0.05). Thefrequencies of the CC, CT, and TT genotypes were 97%, 3%, and 0%, respectively, among the cases, and 97.9%,2.1%, and 0%, respectively, among the controls. CC genotype was more frequent in cases and controls. Thefrequencies of C and T alleles were 98.9% and 1.1% in controls and 98.5% and 1.5% in patient respectively.Our results provide the first evidence that this variant is rare in Iranian population and it may not be a powerfulgenetic predisposing biomarker for prediction GC clinicopathological features in an Iranian population.]]>
p. 4215−4218
2476-762X
Vol.16/No.10
0.05). Although patient age, pathological type,pelvic involvement, and chemotherapy treatment rates were similar (p>0.05), radiotherapy requirement rate anddisease stage were significantly different among the study groups (p<0.05). Conclusions: Hydronephrosis wasfound to be a significant predictor of poor survival in patients with advanced stage cervical cancer, irrespectiveof unilateral or bilateral involvement.While waiting for future studies with larger sample sizes, we believe thatthe FIGO stages in advanced cervical cancer could further be stratified into subgroups according to presenceor absence of hydronephrosis.]]>
p. 4219−4222
2476-762X
Vol.16/No.10
p. 4223−4228
2476-762X
Vol.16/No.10
p. 4229−4235
2476-762X
Vol.16/No.10
p. 4237−4245
2476-762X
Vol.16/No.10
1/2 myometrial invasion(p<0.001), cervical stromal involvement (p=0.002) and higher grade (2-3) (p=0.001) significant for predictingLVSI. In multivariate analysis we found only grade significant for predicting LVSI. Conclusions: Especiallygrade of tumor is a crucial factor for determining LVSI in endometrial cancers with mucinous carcinomatouscomponents.]]>
p. 4247−4250
2476-762X
Vol.16/No.10
p. 4251−4256
2476-762X
Vol.16/No.10
p. 4257−4260
2476-762X
Vol.16/No.10
p. 4261−4264
2476-762X
Vol.16/No.10
p. 4265−4269
2476-762X
Vol.16/No.10
0.05). Conclusions: Epithelial-mesenchymal transition (EMT) tends to appearin poorly-differentiated CSCC tissue, and the up-regulation of vimentin expression is accompanied by highexpression of Ki-67, suggesting that invasion and metastasis readily occur in these tumor cells.]]>
p. 4271−4275
2476-762X
Vol.16/No.10
p. 4277−4283
2476-762X
Vol.16/No.10
11g/dL. Complete response (CR) to external beam RT phase (prior tobrachytherapy) was declared after clinical examinations and computed tomography. The CR rate was noted forboth MWH sub-groups within each of the AHRT and CRT groups. Results: Within the AHRT group, patientswith MWH>11g/dL had a much better CR rate in comparison to those with MWH:10-10.9g/dL (80% vs. 21.1%)which was statistically significant (p 0.0045). Within the CRT group, there was no significant difference in theoutcomes within the MWH>11g/dL and MWH:10-10.9g/dL sub-groups ( CR rates of 80% vs. 61.9%, p=0.4285).Conclusions: The importance of maintaining a minimum hemoglobin level of 11g/dL during RT is much greaterfor patients treated with RT alone, than for patients treated with concurrent chemoradiotherapy. Enhancedhaemoglobin levels during RT may to an extent negate the ill-effects that may otherwise arise due to non-use ofconcurrent chemotherapy.]]>
p. 4285−4289
2476-762X
Vol.16/No.10
p. 4291−4295
2476-762X
Vol.16/No.10
5 000 RUL/PC) and 11 (11/112,9.8%) with pre-treatment low viral load, P<0.05. Conclusions: (1) The persistence HR-HPV DNA is the rootcause of the residual/recurrent disease for the women treated for high-grade CIN; the pre-treatment viral loadand margin can be seen as the predictor. (2) The FU visit beginning at the 6th month post-treatment and lastingat least 24 months with the combination of cytology and HPV testing. (3) Patients with high pre-treatment HPVload, which is considered as one risk of developing the residual/recurrent disease, should be paid more attention(especially above 500RUL/PC) to by clinicians.]]>
p. 4297−4302
2476-762X
Vol.16/No.10
p. 4303−4310
2476-762X
Vol.16/No.10
50 μg/mL) causing G0/G1 cell cycle arrest via apoptosis induction.Caspase colorimetric assays showed markedly increased levels of caspase-3 and caspase-9 activities throughoutthe treatment period. Western blotting of treated HepG2 cells revealed inhibition of NF-κB that triggers themitochondrial-mediated apoptotic signaling pathway by up-regulating cytoplasmic cytochrome c and Bax, anddown-regulating Bcl-2 and Bcl-xL. The current findings suggest DTN has the potential to be developed furtheras an anticancer compound targeting human HCC.]]>
p. 4311−4316
2476-762X
Vol.16/No.10
p. 4317−4321
2476-762X
Vol.16/No.10
p. 4323−4328
2476-762X
Vol.16/No.10
p. 4329−4333
2476-762X
Vol.16/No.10
p. 4335−4338
2476-762X
Vol.16/No.10
10 year (ORs=2.26, 95%CI 1.10-4.63), for those with first-time exposure at age > 25 year (ORs= 2.07, 95%CI1.08-3.94), and for those who had a high cumulative exposure (ORs=2.17, 95%CI 1.03-4.58) when compared withthose considered unexposed. In conclusion, wood dust is likely to be associated with an increased risk of type 2or 3 NPC in the Thai population. The results of this study show that semi-quantitative exposure assessment issuitable for occupational exposure assessment in a case control study and complements the information fromself-reporting.]]>
p. 4339−4345
2476-762X
Vol.16/No.10
0.05). But for RRM1 C37A-T524C genotype, sensitive grouphad higher proportion of high effective genotype than non-sensitive group (p=0.009). And according to the jointdetection of GSTP1 Ile105Val and RRM1 C37A-T524C polymorphisms, the proportion of type A (A/A + higheffective genotype) was significantly higher in sensitive group than in non-sensitive group (p=0.009). Toxicityshowed no correlation with the genotypes between two groups (p>0.05). Conclusions: Compared with singledetection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may bemore helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy.Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict theresponse and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC.]]>
p. 4347−4351
2476-762X
Vol.16/No.10
p. 4353−4356
2476-762X
Vol.16/No.10
p. 4357−4361
2476-762X
Vol.16/No.10
p. 4363−4368
2476-762X
Vol.16/No.10
p. 4369−4376
2476-762X
Vol.16/No.10
p. 4377−4381
2476-762X
Vol.16/No.10
p. 4383−4386
2476-762X
Vol.16/No.10
p. 4387−4392
2476-762X
Vol.16/No.10
p. 4393−4399
2476-762X
Vol.16/No.10
p. 4401−4408
2476-762X
Vol.16/No.10
p. 4409−4419
2476-762X
Vol.16/No.10
20 ng/mL) groups for Kaplan-Meier analysisand Cox proportional hazard regression modeling. Results: The results demonstrated that increased AFPwas associated with longer prothrombin time (PTs), liver capsule invasion, low grade differentiation, and lateBarcelona Clinic Liver Center (BCLC) stage. Moreover, the female patients had a greater prevalence of increasedpreoperative AFP than male patients [284.8 (3.975-3167.5) vs (3.653-140.65); Z-2.895, p=0.004]. The 1-, 3-, and5-year recurrence-free survival (RFS) rates were 78.1, 57.5, and 40.6 % in the AFP-negative group and 61.8,37.7, and 31.4 %, respectively, in the AFP-positive group (log-rank test 8.312, p=0.004). The 1-, 3-, and 5-yearoverall survival (OS) rates were 94.4, 83.8, and 62.3% in the AFP-negative group and 87.2, 60.0, and 36.7%,respectively, in the AFP-positive group. The difference was statistically significant (log-rank test, 16.884, p=0.000).Cox proportional-hazards model identified preoperative AFP to be an independent prognostic predictor of overallsurvival. Conclusions: Preoperative serum AFP is an independent predictor of prognosis among HCC patientsfollowing surgical resection. Female patients have a higher preoperative AFP than their male counterparts.]]>
p. 4421−4427
2476-762X
Vol.16/No.10
p. 4429−4434
2476-762X
Vol.16/No.10
p. 4435−4438
2476-762X
Vol.16/No.10
p. 4439−4445
2476-762X
Vol.16/No.10
p. 4447−4450
2476-762X
Vol.16/No.10
p. 4451−4456
2476-762X
Vol.16/No.10
p. 4457−4463
2476-762X
Vol.16/No.10
p. 4465−4468
2476-762X
Vol.16/No.10
p. 4469−4475
2476-762X
Vol.16/No.10